tbuckley/cabot-search huggingface dataset:
Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.
Authors: A A Epenetos, A J Munro, S Stewart, R Rampling, H E Lambert, C G McKenzie, P Soutter, A Rahemtulla, G Hooker, G B Sivolapenko
Journal: Journal of Clinical Oncology (1987)

Twenty-four patients with persistent epithelial ovarian cancer after chemotherapy with or without external beam irradiation, were treated with intraperitoneally administered 131I-labeled monoclonal antibodies HMFG1, HMFG2, AUA1, H17E2, directed against tumor-associated antigens. Acute side effects were mild abdominal pain, pyrexia, diarrhea, and moderate reversible pancytopenia. One patient developed a subphrenic abscess requiring surgical drainage. Eight patients with large volume disease, ie, greater than 2 cm tumor diameter, did not respond to antibody-guided irradiation and died of progressive disease within 9 months of treatment. Sixteen patients had small-volume (less than 2 cm) disease at the time of treatment with radiolabeled antibody. Seven patients failed to respond, and of nine initial responders, four patients remain alive and free from disease 6 months to 3 years from treatment. Analysis of the data on relapse indicated that doses greater than 140 mCi were more effective than lower doses. We conclude that the intraperitoneal administration of 140 mCi or more of 131I-labeled tumor-associated monoclonal antibodies represents a new and potentially effective form of therapy for patients with small-volume stage III ovarian cancer.
Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia
Authors: Felix Ratjen, Valerie Waters, Michelle Klingel, Nancy McDonald, Sharon Dell, Timothy Ronan Leahy, Yvonne Yau, Hartmut Grasemann
Journal: European Respiratory Journal (2015)

Lung disease in patients with both primary ciliary dyskinesia (PCD) or cystic fibrosis (CF) is associated with impaired mucociliary clearance; however, clinical outcomes are typically worse in CF patients. We assessed whether CF and PCD patients differ in inflammatory response in the airways during pulmonary exacerbation. We first studied clinically stable PCD patients with a spectrum of bacterial pathogens to assess inflammatory response to different pathogens. Subsequently, PCD and CF patients with similar bacterial pathogens were studied at the time of a pulmonary exacerbation and after 21 days of antibiotics treatment. Qualitative and quantitative microbiology, cell counts, interleukin-8 concentrations, and neutrophil elastase activity were assessed in sputum samples obtained before and after treatment. In stable PCD patients, no significant differences were found in sputum inflammatory markers between individuals colonised with different bacterial pathogens. Pulmonary exacerbation severity assessed by a pulmonary exacerbation score and lung function decline from their previous baseline did not differ between CF and PCD patients. Bacterial density for Staphylococcus aureus and Haemophilus influenzae was higher in CF versus PCD (p&lt;0.05), but absolute neutrophil counts were higher in PCD patients (p=0.02). While sputum elastase activity was similar in PCD and CF at the time of exacerbation, it decreased with antibiotic therapy in PCD (p&lt;0.05) but not CF patients. PCD patients differ from those with CF in their responses to treatment of pulmonary exacerbations, with higher neutrophil elastase activity persisting in the CF airways at the end of treatment.
Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration
Authors: Hideki Koizumi, Mariko Kano, Akiko Yamamoto, Masaaki Saito, Ichiro Maruko, Tetsuju Sekiryu, Annabelle A. Okada, Tomohiro Iida
Journal: Ophthalmology (2015)
Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
Authors: K. M. Field, K. Phillips, M. A. Jenkins, J. McKinley, P. Weideman, M. Price, M. Friedlander, S. McLachlan, G. Lindeman, P. Butow
Journal: Journal of Clinical Oncology (2008)

1528 Background: Complementary and alternative medicines (CAMs) are frequently utilized by cancer patients, but there are few data regarding use in well individuals with high cancer risk. Methods: Data on CAM use in females with a strong family history of breast cancer (BC) but no personal cancer history was obtained using a questionnaire mailed 6 years after their enrolment in the kConFab BC family cohort study. CAM use was analysed for demographic and psychosocial predictors of use using multivariate logistic regression. Results: Of the 1,373 women, 1,001 (73%) responded; 109 were excluded as they were not at high cancer risk (spouses or mutation negative), leaving 892 high-risk women. 55% (n=489) used CAM, but only 6% (n=53) used CAM specifically to prevent cancer. The three most common CAMs were vitamins/supplements (n=266, 54%), low fat diet (n=151, 31%) and massage (n=138, 28%). The CAM most frequently used specifically to prevent cancer was green tea (n=19, 26% of all CAM use to prevent cancer), followed by soy rich diet (n=12, 16%) and vitamins/supplements (n=12, 16%). CAM use was independently associated with higher education level (OR 2.56, 95%CI 1.84- 3.56, p<0.001), greater physical activity (OR 1.05 per hour of physical activity/week, 95%CI 1.002–1.10, p=0.04) and lower perceived BC risk (OR 0.99 per percentage of perceived risk, 95%CI 0.98–0.99, p<0.001). Conclusions: Only a small number of women at high risk for BC used CAM specifically to prevent cancer. This suggests that women do not consider CAM as a cancer risk management strategy. The associations between CAM use and higher education and greater physical activity are consistent with the limited literature, but that with lower perceived cancer risk is novel. Clinicians should routinely take a CAM history, given a potential for interactions with chemoprevention medications. No significant financial relationships to disclose.
Abstract A2-40: TOMA OS-seq™: A high efficiency targeted resequencing strategy for detecting gene amplifications, rearrangements, indels, and point mutations in tumor DNA isolated from FFPE solid tumors and plasma
Authors: Yosr Bouhlal, Alexander McKenzie, Austin P. So
Journal: Cancer Research (2015)

Abstract Critical genetic errors, namely specific mutations, are required for the development and maintenance of cancer. Molecular diagnostics that leverage the breadth of next-generation sequencing (NGS) to identify this mutational landscape are therefore becoming an important clinical tool in the precision treatment of cancer. However, widespread adoption of NGS technologies in the clinic is hampered by the complexity of the NGS workflow, and the resulting limits in analytical capabilities due to noise introduced by poor step-wise yields and bias arising from extensive application of PCR. To address these deficiencies, we introduce TOMA OS-Seq™, a complete targeted resequencing workflow designed specifically for the requirements of the clinical laboratory. Based on oligo-selective sequencing, a panel of 96 genes - each with diagnostic or prognostic value - can be sequenced end-to-end from as little as 1 ng of input material, enabling the analysis of DNA purified from fine-needle aspirates and plasma. Utilizing a minimal number of high efficiency processing steps to create a targeted library, this simple workflow minimizes the requirement for PCR amplification, preserving the quantitative relationship among the loci interrogated in the original sample. TOMA OS-Seq™ is therefore capable of detecting of copy number alterations, in addition to rearrangements/fusions, insertions/deletions, and single nucleotide variants. Citation Format: Yosr Bouhlal, Alexander McKenzie, Austin P. So. TOMA OS-seq™: A high efficiency targeted resequencing strategy for detecting gene amplifications, rearrangements, indels, and point mutations in tumor DNA isolated from FFPE solid tumors and plasma. [abstract]. In: Proceedings of the AACR Special Conference on Translation of the Cancer Genome; Feb 7-9, 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 1):Abstract nr A2-40.
Abstract 14758: A Qualitative Study of the Organizational Strategies of High- and Low-Performing PCI Hospitals: Insights From TOP PCI
Authors: Jeptha P Curtis, Karl E Minges, Emily Cherlin, MaryAnne C Elma, Susannah M Bernheim, John Messenger, Henry H Ting, David Berg, Peggy Chen
Journal: Circulation (2013)

Background: Among hospitals that perform percutaneous coronary intervention (PCI) there is a more than two-fold variation in 30-day risk-standardized readmission and mortality rates (RSRR and RSMR)...
Lymphopenia and duration of hospital stay in patients with cancer and febrile neutropenia secondary to chemotherapy
Authors: M. G. McNamara, F. Fitzpatrick, E. Smyth, H. Humphries, O. S. Breathnach, L. Grogan
Journal: Journal of Clinical Oncology (2008)

20590 Background: Cytotoxic chemotherapy is often associated with prolonged neutropenia, alterations in phagocyte function and lymphopenia due to immunosuppressive agents, and disruption of mucosal defense barriers resulting from mucositis and presence of indwelling catheters. The purpose of this study was to establish whether the degree of lymphopenia and recovery time when compared to neutrophil recovery time had any effect on duration of hospital stay. Methods: Fifty pts (27 females, 23 males) with a mean age of 69 yrs, were admitted for treatment of febrile neutropenia from 4/07 to 12/07. Pts with temperature ≥38 degrees celsius and grade 4 (<500/mm3) neutropenia or grade 3 (<1000/mm3) likely to become grade 4 were included. 52% of pts had recorded lymphocytes of less than 400/mm3 on admission. Pts included had breast (36%), non small cell lung carcinoma (NSCLC) (12%), Non-Hodgkin’s lymphoma (NHL) (12%), small cell lung carcinoma, testicular, colorectal (8% each), gastric (6%), ovarian (4%), oesophageal carcinoma (2%), oligoastrocytoma (2%) and mycosis fungoides (2%). No pts received G-CSF. Results: In 22% of pts, bacterial involvement was documented. 73% were caused by gram negative organisms. 27% were caused by gram positive organisms. The most frequently isolated bacteria were Escherichia coli (37%), Enterococci (18%), Arcanobacter (9%), and diarrhoea caused by Campylobacter (27%) and Clostridium difficile (9%). The mean length of hospital stay for pts admitted was 4.1 days (range 2 - 31 days). There was no significant difference in duration of hospital stay in pts with admission lymphocytes of less than 400/mm3 when compared to those with values greater than 400/mm3 (p=0.44). In 38% of pts, time to lymphocyte recovery was delayed in comparison to time to neutrophil recovery. 37% of these pts had breast carcinoma, NHL (21%), colorectal and NSCLC (16% each), gastric and oesophageal carcinoma, 5% each. In these pts whose lymphocyte numbers recovered later than neutrophil count there was a significant increase in length of hospital stay (8.7 days vs. 3.8 days (P<0.01). Conclusions: The duration of hospital stay is longer in pts whose lymphocyte levels recover later than neutrophil count. The biological explanation for this needs further assessment. No significant financial relationships to disclose.
Observations on a Cell Line Producing Mammary Tumor Virus&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: J. A. Sykes, J. Whitescarver, L. Briggs
Journal: JNCI Journal of the National Cancer Institute (1968)

Preliminary tissue culture and electron microscope studies of the cells of ATCC #CCL-51 were undertaken to characterize this cell line. Cells of CCL-51 have been actively producing tumor-inducing mammary tumor virus since the line was initiated in 1962. No specific changes in cellular morphology could be related to the production of mammary tumor virus. An unexpected finding was the relatively few type A particles seen in the cells of CCL-51.
Abstract IA02: The application of integrative sequencing for precision oncology
Authors: Arul Chinnaiyan
Journal: Cancer Research (2015)

Abstract Studies of the genomic landscape of human cancers have demonstrated that most solid cancers have a multitude of mutations, a subset of which may be “actionable” with current drugs. Thus, the personalization of therapy for cancer will require molecular characterization of unique and shared genetic aberrations. Patients who have advanced/refractory cancer and are candidates for clinical trials could potentially benefit by identifying eligibility for “targeted” drugs based on the “actionable” genes in their specific tumor. Growing technological advances in genomic sequencing has now made it possible to consider the use of sequence data in a clinical setting. MI-ONCOSEQ initiative brings together expertise at the University of Michigan including clinical oncology, cancer genetics, bioinformatics, clinical pathology, social and behavioral sciences, and bioethics in order to implement clinical cancer sequencing. Our study identifies patients with advanced or refractory cancers that are eligible for clinical trials, consent them to the study, obtain biospecimens (tumor tissue, germline tissue) and store clinical data. The clinical sequencing team processes biospecimens, performs comprehensive sequencing and analysis of tumors to identify point mutations, copy number changes, rearrangements/gene fusions, and aberrant gene expression. Finally, a multi-disciplinary Sequencing Tumor Board deliberates on return of actionable or incidental genomic results. Citation Format: Arul Chinnaiyan. The application of integrative sequencing for precision oncology. [abstract]. In: Proceedings of the AACR Special Conference on Computational and Systems Biology of Cancer; Feb 8-11 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 2):Abstract nr IA02.
Abstract 18377: Hypoplastic Left Heart Syndrome Derived Cardiac Stem Cells Show a Strong Regenerative Ability
Authors: Rachana Mishra, Sudhish Sharma, Ling Chen, Savitha Desmukh, Sunjay Kaushal
Journal: Circulation (2013)

Background: Human adult c-kit+ cardiac stem cells (CSCs) alleviates post-myocardial infarction left ventricle dysfunction in animal models and a Phase I clinical study. The regenerative capacity of CSCs in the very young patients with non-ischemic congenital heart defects has not been explored, even in the most surgically challenging Hypoplastic Left Heart Syndrome (HLHS) patients. We hypothesized that isolated HLHS neonatal-derived CSCs may have higher regenerative abilities than adult-derived CSCs and might address the anatomical deficiency of HLHS myocardium. Methods and Results: Human specimens were obtained during routine cardiac surgical procedures from right atrial appendage tissue discarded from 2 age groups: neonates and adults patients. We developed a reproducible isolation method that generated c-kit+ cells using immune-activated magnetic bead selection, regardless of the initial weight or age. Both groups had similar expression profile for c-kit+ (&gt;85%), Ki67, TnT, GATA4+, and were negative for tryptase, collagen, and CD45. Both groups had similar proliferation doubling times. The neonatal-derived c-kit+ cells secreted higher levels of VEGF-A, ANG, and SDF-1α when compared to adult-derived c-kit+ cells. When transplanted into infarcted myocardium, neonatal-derived c-kit+ cells had a significantly higher ability to preserve myocardial function, prevent adverse remodeling, and enhance blood vessel preservation when compared to adult-derived c-kit+ CSCs. Conclusions: HLHS neonatal-derived c-kit+ cells have a strong regenerative ability when compared with adult-derived c-kit+ cells that may depend on angiogenic cytokines. This has important implications in the potential use of CSCs in future HLHS clinical trials.
제5차 대한간학회 춘계학술대회 초록집 : 사염화탄소에 의해 급성 손상된 간에서 간성상세포의 활성화 시기와 비타민 E의 효과
Authors: 송종원 ( Song Jong Won ), 이관식 ( Lee Gwan Sig ), 박영년 ( Park Yeong Nyeon ), 이광재 ( Lee Gwang Jae ), 한광협 ( Han Gwang Hyeob ), 전재윤 ( Jeon Jae Yun ), 문영명 ( Mun Yeong Myeong )
Journal: Clinical and Molecular Hepatology (1999)
Preoperative functional status in patients with lung tuberculosis before pneumonectomy
Authors: Larisa Kiryukhina, Pavel Gavrilov, Igor Savin, Olga Volodich, Olesya Tamm, Armen Avetisyan, Piotr Yablonskiy
Journal: European Respiratory Journal (2014)

Clinical guideline about functional evaluation of lung cancer patients before lung resection is well known. Patients with lung tuberculosis (LT) have another pathogenesis and morphological changes of lungs. However importance of the functional status in estimating risk of lung resections for patients with LT is not so definitely.

Aim: To evaluate preoperative pulmonary function status in patients with LT who were performed pneumonectomy.

Materials and Methods: Fifty-one patients with LT were studied. Spirometry, bodyplethysmography, diffusion capacity, computed tomography and perfusion scintigraphy were performed before pneumonectomy.

Results. There were obstructive disorders (OD) in 40 patients (FEV1=65,4% pred., RV=152,7% pred., 95%ДИ 142,0-163,4), restrictive disorders (RD) in 3 patients and mixed disorders (MD) in 5 patients (FEV1=52,6% pred., 95%CI 43,2,6-62,11; TLC=73,7% pred., 95%ДИ 66,6-80,8) and normal ventilation parameters in 3 patients (FEV1 from 105,6% to 123,1% pred.). Patients with OD had significant decline of DLCO (DLCO=55,7% pred., 95%CI 52,5-58,9). Patients with RD and MD had severe decline of DLCO (DLCO=40,0%pred., 95%CI 31,8-48,2). Even patients without ventilation disorders had decline of DLCO (from 62,8% to 78,9% pred.). Only 3 patients with OD but all patients with MD had DLCO less 40% pred. There was not registered 30-day postoperative lethality in all group of the surveyed patients.

Conclusions. All patients with LT even without ventilation disorders had decrease of DLCO. Decline of DLCO had been especially expressed in patients with MD. The meaning of DLCO as criterion of functional operability demands the further analysis for patients with LT.
The Place of Neuroimaging in the Assessment of Cerebral Small Vessel Disease
Authors: Wolf-Dieter Heiss
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
An Attempt to Induce Malignant Transformation of Cells &lt;italic&gt;In Vitro&lt;/italic&gt; by Intermittent Anaerobiosis
Authors: Sanford, K. K.
Journal: JNCI Journal of the National Cancer Institute (1965)

Journal Article An Attempt to Induce Malignant Transformation of Cells In Vitro by Intermittent Anaerobiosis Get access K. K. Sanford K. K. Sanford Laboratory of Biology, National Cancer Institute,3Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 35, Issue 4, October 1965, Pages 719–725, https://doi.org/10.1093/jnci/35.4.719 Published: 01 October 1965 Article history Received: 11 February 1965 Published: 01 October 1965
Accuracy of RANK/OPG and CXCR4 compared to hormone receptors in predicting bone metastases in patients with breast cancer.
Authors: T. Ibrahim, E. Sacanna, M. Gaudio, L. Mercatali, R. Ricci, E. Scarpi, P. Serra, F. Fabbri, L. Serra, D. Amadori
Journal: Journal of Clinical Oncology (2010)

e11507 Background: The RANK/RANK-L/OPG system is an important part of the bone metastasization process. CXCL12 is overexpressed in bone and like its receptor, CXCR4, is a determinant of organ tropism. The objective of the present study was to evaluate whether the expression of these markers in primary breast cancer can predict the onset of bone metastases. Methods: Marker expression was evaluated by immunohistochemical staining in paraffin-embedded sections of primary breast cancers from 40 individuals: 10 patients (median age 64 years, range 48-78) were disease-free (DFP) at a median of 9.8 (range 6.9-11.5) years, while 30 (median age 67 years, range 42-87) had relapsed. Within the latter subgroup, 10 (median age 66 years, range 42-87) had visceral metastases (VMP), and 20 (median age 69 years, range 42-87) had bone metastases (BMP). Results: In the overall series, 68% of tumors were ER-positive and 45% were PgR-positive. Moreover, 17.5% of tumors were positive for RANK, 22.5% for OPG and 25% for CXCR4. No significant associations were observed among the different markers. Analyzing the different patient subgroups, it was seen that RANK and OPG were equally expressed in 20% of DFP and in 25% of BMP. CXCR4 was expressed in only 10% of DFP but in 45% of BMP. Moreover, 20% of VMP expressed OPG but none showed RANK or CXCR4 expression. None of the patients expressed RANKL. The highest sensitivity in predicting bone metastasis was observed for ER positivity (80%), which, however, showed low specificity (30%), followed by triple positive RANK, CXCR4 and OPG (75%). Moreover, the highest specificity was observed for CXCR4 (90%) followed by RANK or OPG (80%). Conclusions: Our results indicate that, despite high sensitivity, ER-positive status is burdened by low specificity. Conversely, RANK, OPG, and CXCR4 expression would appear to be a more accurate predictor of bone relapse. The validation of these results is ongoing in a larger series of patients with breast cancer. No significant financial relationships to disclose.